Bassendine M F, Chadwick R G, Salmeron J, Shipton U, Thomas H C, Sherlock S
Gastroenterology. 1981 May;80(5 pt 1):1016-22.
A controlled trial has been undertaken to evaluate adenine arabinoside in the treatment of hepatitis B surface antigen-positive chronic liver disease. Thirteen patients (7 hepatitis B virus DNA polymerase and hepatitis B e antigen-positive, 6 DNA polymerase negative and hepatitis B e antibody-positive) were treated with adenine arabinoside. Eleven comparable patients served as controls, and follow-up was for 6 mo. In the 7 hepatitis B e antigen-positive patients, adenine arabinoside produced a fall in DNA polymerase activity during treatment. When this effect was sustained, it was followed by a loss of e antigen (3 patients). Hepatitis B surface antigen concentrations and aspartate transaminase levels fell significantly at 6 mo (p less than 0.05) in the treated group compared with controls. In the hepatitis B e antibody-positive patients, adenine arabinoside treatment produced no significant change in hepatitis B surface antigen concentrations or aspartate transaminase levels at 6 mo as compared with controls. Adenine arabinoside would appear to reduce either transiently or permanently, hepatitis B virus replication, and it may therefore be useful in reducing the infectivity of some carriers of this virus. In the dose used, adenine arabinoside was ineffective in clearing hepatitis B surface antigen from the serum and eradicating hepatitis B virus from the liver, but combination with other antiviral or immunostimulant agents may enhance its therapeutic effectiveness.
已进行一项对照试验以评估阿糖腺苷治疗乙型肝炎表面抗原阳性慢性肝病的效果。13例患者（7例乙型肝炎病毒DNA聚合酶和乙型肝炎e抗原阳性，6例DNA聚合酶阴性且乙型肝炎e抗体阳性）接受了阿糖腺苷治疗。11例可比患者作为对照，随访6个月。在7例乙型肝炎e抗原阳性患者中，阿糖腺苷在治疗期间使DNA聚合酶活性下降。当这种作用持续时，随后出现e抗原消失（3例患者）。与对照组相比，治疗组在6个月时乙型肝炎表面抗原浓度和天冬氨酸转氨酶水平显著下降（p<0.05）。在乙型肝炎e抗体阳性患者中，与对照组相比，阿糖腺苷治疗在6个月时乙型肝炎表面抗原浓度或天冬氨酸转氨酶水平无显著变化。阿糖腺苷似乎可暂时或永久降低乙型肝炎病毒复制，因此可能有助于降低该病毒某些携带者的传染性。在所使用的剂量下，阿糖腺苷在清除血清中的乙型肝炎表面抗原和从肝脏中根除乙型肝炎病毒方面无效，但与其他抗病毒或免疫刺激剂联合使用可能会提高其治疗效果。
